TREATMENT OF HER2 NEGATIVE, MAMMAPRINT HIGH RISK 2 BREAST CANCER
The invention relates to a PARP inhibitor, an immune checkpoint inhibitor, or a combination thereof, for use as a medicament. The invention further relates to a kit of parts and to a pharmaceutical composition comprising a PARP inhibitor and an immune checkpoint inhibitor, preferably for use in a method of treating a breast cancer.
1 - 15 . (canceled)
16 . A method of treating an individual, comprising administering to an individual with human epidermal growth factor receptor 2 (HER2) negative, MammaPrint high risk 2 (MP2) breast cancer, a poly [ADP-ribose] polymerase (PARP) inhibitor, an immune check point inhibitor, or a combination of a PARP inhibitor and an immune check point inhibitor.
17 . The method of claim 16 , wherein the PARP inhibitor is selected from the group consisting of olaparib, rucaparib, pamiparib, niraparib and talazoparib.
18 . The method of claim 16 , wherein the immune check point inhibitor is selected from the group consisting of tremelimumab, pembrolizumab, nivolumab, pidilizumab, cemiplimab, atezolizumab, avelumab and durvalumab.
19 . The method of claim 16 , comprising administering to the individual a combination of a PARP inhibitor and an immune check point inhibitor.
20 . The method of claim 19 , wherein the PARP inhibitor is administrated simultaneously with, separately from, or sequentially to the immune check point inhibitor.
21 . The method of claim 16 , wherein the method further comprises administering a taxane.
22 . The method of claim 16 , wherein the method further comprises administering a taxane selected from the group consisting of paclitaxel, docetaxel, and cabazitaxel.
23 . The method of claim 16 , wherein the individual has a HER2 negative, ER positive breast cancer.
24 . The method of claim 16 , wherein the HER2 status is determined by TargetPrint or by BluePrint.
25 . A pharmaceutical composition comprising a PARP inhibitor and an immune check point inhibitor.
26 . The pharmaceutical composition according to claim 25 , wherein the PARP inhibitor is selected from the group consisting of olaparib, rucaparib, pamiparib, niraparib and talazoparib.
27 . The pharmaceutical composition according to claim 25 , wherein the immune check point inhibitor is selected from from the group consisting of tremelimumab, pembrolizumab, nivolumab, pidilizumab, cemiplimab, atezolizumab, avelumab and durvalumab.
28 . The pharmaceutical composition according to claim 25 , further comprising a taxane.
29 . The pharmaceutical composition according to claim 25 , further comprising a taxane selected from the group consisting of paclitaxel, docetaxel, and cabazitaxel.